Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat
(AB680) in subjects with untreated advanced biliary tract cancers (BTC). The study will
include a safety run-in involving 6 study participants. The goal of the safety run-in is to
screen for early safety signals of the proposed drug combination. Trial enrollment can
continue while full safety assessment is being completed for the first 6 subjects.
Participants will receive 4 cycles of combination therapy as described. After 4 cycles (~6
months), cisplatin will be discontinued, while gemcitabine, zimberelimab (AB122), and
quemliclustat (AB680) will be continued. Subjects will be treated until disease progression
or development of intolerable toxicities. In total, there will be up to 39 participants on
the study.
Phase:
Phase 2
Details
Lead Sponsor:
Nataliya Uboha
Collaborators:
Arcus Biosciences, Inc. Gilead Sciences University of Wisconsin, Madison